Alexandre Ehrhardt is an Adjunct Professor with a demonstrated history of working in Clinical Laboratory. Skilled in Toxicology and Pharmacology, Immunology and Hematology. Hold a strong professional education with a Master Degree in Pharmacology and Therapeutics focused in Development of Bioactives Compounds from Universidade Federal do Rio Grande do Sul (Brasil). Currently is developing a project focusing on Biomaterials with antibacterial and antifungal activity.
A plethora of bacteria and fungi are able to alternate planktonic growth and community growth, commonly referred as biofilms. Orthodontic appliances favors the colonization by Candida albicans yeasts (C. tropicalis, C. parapsilosis and C. krusei) in the saliva of individuals with or without clinical manifestations of candidiasis. The concern of biofilm formation during orthodontic treatment, associated with dental plaque formation and periodontal diseases is of concern considering that Candida spp. biofilms have a great resistance to antifungal drugs according to several studies. In order to minimize this problem, it is proposed to add antifungal properties to a biomaterial by modifying a glass ionomer cement with the addition of an imidazolium salt: C16MImCl. The process consisted of an structural modification of a commercially available glass ionomer cement by inserting the imidazolium salt 1-n-hexadecyl-3-methylimidazolium chloride (C16MImCl), generating a new biomaterial with antifungal biofilm activity. Test specimens were prepared using a commercial glass ionomer cement to which 10 ppm of cetylpyridinium chloride (CPC) as a reference ionic antifungal agent and C16MImCl were added. The feasibility and hypoallergenicity of the new biomaterial were assessed by microhardness plastic deformation and chorioallantoic membrane assays. Colony counting and SEM images evaluated the modified specimens’ antibiofilm activity against three multidrug-resistant Candida species. The modified glass ionomer cement presented a strong antibiofilm activity against Candida spp., without losing its original micromechanical and hypoallergenic properties. A good biofilm penetration was observed, breaking the fungal protection and characterizing an antifungal effect even at very low concentrations.
Besides that, the CPC and C16MImCl incorporation into the glass powder and subsequent polymerization reaction did not modify the microhardness of the TS. This initial step is of utmost importance, since the inclusion of additives can compromise the physical–mechanical properties of GIC. Considering the demand for biomaterials with antibiofilm activity, this new biomaterial could potentially improve the classical ionomer cement applicable in many areas of dentistry.
Dr. Jyoti Sharma, currently working as Assistant Professor in the Department of Pharmacology, PGIMS, Rohtak. Actively involved in teaching of MD, MBBS, BDS & Allied Health Sciences. Work profile also includes Detection & reporting of ADRs, Quality assurance (e.g. completeness and integrity of data) of uploaded ADRs, Assessment of Individual Case Safety Reports, Causality assessment, Clinical and experimental Research. Has a total of 7 years of teaching experience. Recipient of Dr. R. D Kulkarni Award for Third position in Poster presentation at South Asian College of Clinical Pharmacology an Affiliate of American College of Clinical Pharmacology in Eleventh Annual Conference “Clinical Pharmacology: Contributing to Global Health and Policies” held from 29th April – 2nd May 2018. The above study was done to find out the anxiolytic and antidepressant effect of Palonosetron as no studies have been found till date.
Background: Depression and anxiety remain serious problems in given unexpected circumstances like Covid-19. Serotonin is one of the most important neurotransmitters influencing mental health and a potential target for pharmacological treatments. 5HT3 receptor antagonists like ondansetron; mainly used for management of acute & delayed cancer chemotherapy induced emesis, has shown anxiolytic and antidepressant effect in various studies. Another 5HT3 antagonist; Palonosetron approved for delayed cancer chemotherapy induced emesis, has yet not been studied for anxiolytic and antidepressant effects. Material & Methods: Light-dark compartment model was used for anti-anxiety effect evaluation and Swim despair test was used for evaluation of anti-depressant effect. Swiss albino mice were used and randomly divided in 5 groups of 6 each to receive following 5 treatments: Group 1Control i.e normal saline (0.1 ml/10 g of body weight i.p.), Group 2: Diazepam (1mg/kg i.p), Group 3: Fluoxetine (18mg/kg i.p), Group 4: Palonosetron (0.025 mg/kg i.p), Group 5: Palonosetron (0.05mg/kg i.p) in each animal model. In light-dark compartment model efficacy was assessed at end of 15, 30, 60, 120, 180 & 300mins by observing time spent in light compartment and number of transitions made between both compartments. In Swim despair test efficacy was assessed by recording of immobility period after 1 hr & 24 hrs of drug administration. Results: Time spent in the light compartment at the end of 30, 60 and 120 min with palonosetron (0.05mg/kg) was statistically significant more as compared to control & fluoxetine. No of transitions made between both compartments also increased with palonosetron (0.05mg/kg) at the end of 15, 30, 60 & 120 mins as compared to control and fluoxetine groups. In Swim despair test palonosetron (0.05mg/kg) showed statistically significant antidepressant activity as compared to control and fluoxetine group at 1 hr & 24 hrs respectively. Conclusion: Palonosetron (0.05mg/Kg) possesses significant antidepressant & anti-anxiety activity in animal models.
Recent Publications (minimum 5)
(COVID-19) Corona virus disease 2019 is related to severe lung damage and it is likely to cause multi-organ failure, finding a definitive treatment challenging researchers worldwide. Recently dexamethasone has demonstrated significant effects in COVID-19; it reduced mortality and improved recovery. It suppresses immune response and inhibits inflammatory factors, and hence it reduces inflammation and prevents progression to severe form of COVID-19 that caused by excessive cytokine release. Indeed, current evidence about dexamethasone role in the management of COVID-19 is insufficient. The pathophysiology of COVID-19 and dexamethasone action are key points behind its contribution in the treatment of this panepidemic.